Dianthus Therapeutics, Inc. /DE/ SEC filings DNTH
Dianthus Therapeutics, Inc. /DE/ has 658 filings in SEC EDGAR's recent list, going back to Nov 23, 2016. Its latest annual report, Form ARS, was filed on Apr 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| S-3ASR | Automatic shelf registration | Sep 18, 2026 | — |
| 424B5 | Prospectus supplement | Mar 11, 2026 | — |
| S-3MEF | Filing | Mar 10, 2026 | — |
| 424B5 | Prospectus supplement | Mar 9, 2026 | — |
| S-8 | Employee stock plan registration | Mar 9, 2026 | — |
| S-3 | Shelf registration | Jan 28, 2026 | — |
| 424B5 | Prospectus supplement | Sep 11, 2025 | — |
| 424B5 | Prospectus supplement | Sep 8, 2025 | — |
| S-8 | Employee stock plan registration | Mar 11, 2025 | — |
| 424B5 | Prospectus supplement | Oct 11, 2024 | — |
| 424B3 | Prospectus | Oct 11, 2024 | — |
| S-3 | Shelf registration | Oct 1, 2024 | — |
| S-3 | Shelf registration | Oct 1, 2024 | — |
| 424B3 | Prospectus | Sep 16, 2024 | — |
| S-8 | Employee stock plan registration | Aug 8, 2024 | — |
| 424B3 | Prospectus | Aug 8, 2024 | — |
| 424B3 | Prospectus | May 28, 2024 | — |
| 424B3 | Prospectus | May 9, 2024 | — |
| S-8 | Employee stock plan registration | Mar 21, 2024 | — |
| S-1/A | Amended registration statement | Mar 21, 2024 | — |
| S-1/A | Amended registration statement | Feb 7, 2024 | — |
| S-1/A | Amended registration statement | Dec 21, 2023 | — |
| S-8 | Employee stock plan registration | Oct 4, 2023 | — |
| S-3 | Shelf registration | Oct 4, 2023 | — |
| 424B3 | Prospectus | Aug 1, 2023 | — |
| S-4/A | Filing | Jul 31, 2023 | — |
| S-4/A | Filing | Jul 17, 2023 | — |
| S-4/A | Filing | Jun 22, 2023 | — |
| S-4 | Registration for a merger or exchange | May 15, 2023 | — |
| 424B5 | Prospectus supplement | Aug 18, 2022 | — |
| S-3 | Shelf registration | Aug 4, 2022 | — |
| S-8 | Employee stock plan registration | Mar 8, 2022 | — |
| 424B3 | Prospectus | Jul 12, 2021 | — |
| S-3 | Shelf registration | Jun 25, 2021 | — |
| S-8 | Employee stock plan registration | Mar 3, 2021 | — |
| 424B5 | Prospectus supplement | Jun 25, 2020 | — |
| 424B5 | Prospectus supplement | Jun 24, 2020 | — |
| S-8 | Employee stock plan registration | Mar 3, 2020 | — |
| 424B5 | Prospectus supplement | Aug 21, 2019 | — |
| S-3 | Shelf registration | Aug 8, 2019 | — |
| S-8 | Employee stock plan registration | Aug 8, 2019 | — |
| 424B4 | Prospectus | May 2, 2019 | — |
| S-1 | Registration statement | Apr 29, 2019 | — |
| S-8 | Employee stock plan registration | Mar 19, 2019 | — |
| S-8 | Employee stock plan registration | Jun 22, 2018 | — |
| 424B4 | Prospectus | Jun 21, 2018 | — |
| FWP | Free writing prospectus | Jun 19, 2018 | — |
| S-1/A | Amended registration statement | Jun 19, 2018 | — |
| S-1/A | Amended registration statement | Jun 18, 2018 | — |
| S-1/A | Amended registration statement | Jun 8, 2018 | — |
| S-1 | Registration statement | May 24, 2018 | — |
Showing 51 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- DNTH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1690585
- Former names
- Magenta Therapeutics, Inc. (until Sep 8, 2023)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.